Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 17

1157P - Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry

Date

14 Sep 2024

Session

Poster session 17

Topics

Tumour Site

Neuroendocrine Neoplasms

Presenters

Jorge Hernando Cubero

Citation

Annals of Oncology (2024) 35 (suppl_2): S749-S761. 10.1016/annonc/annonc1598

Authors

J. Hernando Cubero1, N. Martinez Lago2, M. Mitjavila3, A. Garcia-Burillo4, V. Pubul5, P. Bello6, J.M. Cano7, B. Llana8, M. Castellón9, E. Rodeño10, A. Piñeiro11, C. Soldevilla12, M. Nevares13, J. Aller14, U. Anido Herranz15, B. Carnero Lopez16, Z. Nogareda5, A. Garcia Alvarez17, P. Jimenez Fonseca18, J. Capdevila Castillon19

Author affiliations

  • 1 Medical Oncology Department, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2 Medical Oncology, CHUF - Complejo Hospitalario Universitario de Ferrol - Hospital Arquitecto Marcide, 15405 - Ferrol/ES
  • 3 Nuclear Medicine, Hospital Universitario Puerta De Hierro, 28222 - Majadahonda/ES
  • 4 Nuclear Medicine, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 5 Nuclear Medicine, Complexo Hospitalario Universitario de Santiago de Compostela, 15701 - Santiago de Compostela/ES
  • 6 Nuclear Medicine, Hospital Universitario y Politécnico La Fe, 46026 - Valencia/ES
  • 7 Medical Oncology Department, Hospital General Ciudad Real, 13005 - Ciudad Real/ES
  • 8 Nuclear Medicine, Hospital Universitario Central de Asturias, 33006 - Oviedo/ES
  • 9 Nuclear Medicine, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 - El Palmar/ES
  • 10 Nuclear Medicine, Hospital Universitario Cruces, 48903 - Barakaldo/ES
  • 11 Nuclear Medicine, Hospital Universitario Virgen de las Nieves, 18014 - Granada/ES
  • 12 Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 09041 - Barcelona/ES
  • 13 Nuclear Medicine, Hospital Universitario de Burgos, 09006 - Burgos/ES
  • 14 Endocrinology, Hospital Universitario Puerta De Hierro, 28222 - Majadahonda/ES
  • 15 Medical Oncology, CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, 15706 - Santiago de Compostela/ES
  • 16 Medical Oncology, Hospital Universitario Lucus Augusti, Lugo/ES
  • 17 Medical Oncology Dept., Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 18 Medical Oncology, Hospital Universitario Central de Asturias, 33006 - Oviedo/ES
  • 19 Medical Oncology, Vall d'Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1157P

Background

PRRT is a crucial treatment for p with somatostatin receptor-expressing NET. Strategy of re-treating with PRRT (rePRRT) to enhance clinical benefit is gaining attention. Standardized protocols for the efficacy, safety and rePRRT administration remain undefined across centers.

Methods

SEPTRALU, a Spanish national registry, comprises over 500 p with NET treated with PRRT. This study explores rePRRT instances to identify variables associated with treatment outcomes.

Results

71 rePRRT p (41% female, 55y) were included. Main primary location was ileal (35%) and pancreatic (34%), with 35% being functional. Most had hepatic (85%), bone (25%) and peritoneal (14%) metastases. Histologically, mean Ki67 was 10% with 32% Ki67 ≥10%; WHO Grade 1: 37%, G2: 49%, G3: 14%). First PRRT (PRRT1) was given as 2nd (35.5%) and 3rd line (27%). All p received 4 doses, achieving an overall response rate (ORR) of 61.7% and progression free survival (PFS) of 35 months (m). Average interval between end of PRRT1 and rePRRT was 29.3 m. For rePRRT, p received 1 to 4 doses at rates of 100%, 66%, 24% and 17%, respectively. Discontinuation was mainly due to progression (18%). ORR for rePRRT was 17.6% with a clinical benefit rate of 58.8% and PFS was not reached after 10 months of follow-up, with a 10-months PFS rate of 78%. No new toxicity alerts were reported. Univariate analysis identified predictors for rePRRT radiological response: previous PRRT1 response (p 0.004), Ki67 >30% (p 0.033) and WHO G3 (p 0.035).

Conclusions

RePRRT offers a viable therapeutic strategy for NETs, with favorable efficacy and identificable response predictors, notably prior PRRT response. Ongoing trials will yield insights into the optimal rePRRT duration and its sequencing within therapeutic algorithms.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

J. Hernando Cubero: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Novartis, AAA, Angelini, Pfizer, Roche. U. Anido Herranz: Financial Interests, Personal, Invited Speaker: Advanced Accelerator Applications, Ipsen, AstraZeneca, Merck, Pfizer, Astellas, Bayer, Eisai, BMS, Kyowa Kirin, Rovi; Financial Interests, Personal, Advisory Board: Advanced Accelerator Applications, Ipsen, AstraZeneca, Merck, Pfizer, Bayer; Financial Interests, Personal, Other, Travel expenses: Esteve. A. Garcia Alvarez: Financial Interests, Personal, Advisory Board: ADACAP (Novartis); Other, Expenses (Travel, Congress inscription): Advanz, Eisai, Ipsen, ADACAP (Novartis). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.